This workshop will delve into the move beyond symptom control toward diseasemodifying therapies, earlier intervention, and precision targeting of responder subgroups. Discuss defining patient endotypes, handling variability, anticipating nonresponders, and designing trials capable of proving superiority in crowded spaces like AD, psoriasis, HS, and CSU. Participants will examine early-diagnosis challenges, biomarker-guided recruitment, and emerging combinations/bispecifics.

What attendees will gain: practical strategies to redesign clinical programs for long-term remission and subpopulation-specific efficacy.

• What is the value of identifying meaningful patient subpopulations using proteomics/genomics for trial eligibility?
• What evidence is required to justify early use of advanced therapies?
• How can we push beyond plateaus in efficacy?
• How do misdiagnosis and diagnostic delay impact clinical trial outcomes?